Altimmune, Inc.
Display and export data
General & Ratios
Financial Statements
/
In the 'original' view, the statements are displayed just as they are being reported by the company.
In the 'standardised' view, the statements are displayed in a standardised format (line items are identical for all companies).
Add data
Click on one of the orange fields in the profile to add new information
Edit or review data
Legend (for Financial Statements)
Verified data (?)
Non-verified data (?)
Click on a coloured field in the profile to review the data
Close sidebar
Loading: 100%
Altimmune, Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees (as per )no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker ALTno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 1702468
datesClosing price (adj.)
13.10.20172.50
11.10.20172.64
04.10.20172.29
27.09.20172.31
20.09.20172.53
13.09.20172.60
06.09.20172.50
30.08.20172.50
23.08.20172.26
16.08.20172.17
09.08.20172.25
02.08.20172.25
26.07.20172.80
19.07.20172.50
12.07.20172.59
05.07.20173.18
27.06.20173.47
20.06.20173.74
13.06.20174.15
06.06.20174.12
30.05.20174.17
23.05.20174.55
16.05.20174.95
09.05.20176.14
02.05.20170.69
25.04.20170.70
18.04.20170.78
11.04.20170.77
04.04.20170.79
28.03.20170.82
21.03.20170.81
14.03.20170.78
07.03.20170.63
28.02.20170.90
21.02.20171.03
14.02.20171.10
07.02.20171.37
31.01.20170.80
24.01.20170.86
17.01.20170.86
10.01.20170.88
03.01.20170.85
27.12.20160.84
19.12.20160.84
12.12.20160.84
05.12.20160.81
28.11.20160.80
21.11.20160.80
14.11.20160.75
07.11.20160.72
31.10.20160.71
24.10.20160.72
17.10.20160.73
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
 2.50n/a
Market Capitalisation
in million USD
 39n/a
Enterprise Value
in million USD
 0n/a
Common Shares Outstanding
as per Jun 30, 2017
 15,424,891n/a
Preferred Shares Outstanding
as per Jun 30, 2017
 n/a
Average Basic Shares Outstanding
TTM
 52,276,277n/a
Average Diluted Shares Outstanding
TTM
 52,627,117n/a
Index Membership
n/a
Business Summary
Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It has two vaccine delivery platforms, RespirVec and Densigen.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 0n/a
Receivables 0n/a
Total Current Assets 0n/a
PP&E 0n/a
Total Assets 0n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 0n/a
Long-Term Debt 0n/a
Total Liabilities 0n/a
Total Equity 0n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value n/a
Other Ratios
Current Ratio 0.0%n/a
Liabilities to Equity Ratio 0.0%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (22 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Total revenue and grants and contracts
21
24
25
18
10
11
5
Research and development
21
21
20
15
9
5
5
General and administrative
18
14
12
13
11
6
12
Restructuring expense
0
0
0
0
0
3
0
Depreciation
6
0
0
0
0
0
0
Total operating expenses
45
36
31
29
20
14
16
Loss from operations
-24
-12
-6
-11
-10
-3
-11
Interest and Dividend Income, Operating
0
0
0
0
0
0
0
Gain on sale of assets held for sale
0
1
0
0
0
0
0
Interest Income (Expense), Net
-6
0
0
0
0
0
0
Realization of cumulative translation adjustment
0
0
1
0
0
0
0
Change in fair value of derivative instruments
-5
7
1
0
1
0
-1
Other income - litigation
0
0
0
0
0
0
217
Other income (expense)
0
0
0
0
0
0
0
Total other income (expense)
-11
8
2
-1
0
0
216
Net loss before income tax benefit
-35
-4
-5
-12
-10
-3
205
Income tax provision
0
0
0
0
0
0
-11
Net Income (Loss)
-35
-4
-5
-12
-10
-3
194
Remarks
restated on Mar 14, 2013 n/a
calculated values,
restated on Mar 11, 2014 n/a
calculated values,
restated on Mar 11, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (43 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash and cash equivalents
12
11
13
10
19
16
3
Restricted cash
0
0
0
0
0
0
0
Accounts receivable
5
4
2
1
0
1
0
Short-term investments
0
0
0
0
0
0
0
Unbilled accounts receivable
4
3
4
2
0
1
0
Prepaid expenses and other current assets
1
1
1
0
0
0
0
Tax refund receivable
0
0
0
0
0
0
1
Restricted cash
0
0
0
0
0
0
0
Assets held for sale
1
0
0
0
0
0
0
Total current assets
24
20
20
14
19
17
4
Property and equipment, net
1
1
0
0
0
0
0
Intangible assets, net
0
0
0
0
0
0
15
Other long-term assets and deferred costs
0
0
0
0
0
0
0
Goodwill
2
2
2
2
2
2
19
Total assets
27
23
23
17
22
20
38
Liabilities and owners' equity
Notes payable
0 0
0 0
0 0
0 0
0 0
0 0
0 458629
Accounts payable
3 3128203
1 1445700
2 1697280
1 1128172
0 391396
1 521122
2 2005208
Accrued expenses and other current liabilities
3 3035284
3 2655330
2 2328877
3 3182687
1 1195412
1 1248708
3 2972745
Current portion of deferred revenue
0 0
1 514312
1 1381755
0 341723
0 0
0 0
0 19753
Current portion of deferred rent
0 0
0 0
0 0
0 51663
0 0
0 0
0 14388
Dividends payable
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Accrued income taxes payable
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Current portion of long-term debt
0 0
0 0
1 749997
1 999996
1 746146
0 0
0 0
Other short-term borrowings
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short-term debt
0 0
0 0
1 1330507
1 1091740
0 0
0 0
0 0
Current portion of derivative instruments
0 0
0 0
0 0
0 0
0 178509
0 16411
0 0
Total current liabilities
6 6163487
5 4615342
7 7488416
7 6795981
3 2581789
2 2179441
5 5470723
Unvested restricted stock liability
0 0
0 0
0 0
0 0
0 0
0 0
0 1001
Long-term debt
0 0
0 0
0 0
0 0
0 0
0 0
1 525950
Deferred revenue, long-term portion
0 0
0 0
2 1704108
1 730279
0 0
0 0
0 179424
Other long-term liability
0 0
0 0
0 0
0 0
0 70326
0 11250
0 0
Accrued restructuring expenses, less current portion
0 0
0 0
0 0
0 0
0 0
0 108641
0 0
Other long-term liabilities
0 461858
0 449709
1 579427
1 588745
0 493137
0 433407
0 15914
Derivative instruments, less current portion
8 8362995
2 1886652
1 1295613
2 1688572
1 629170
0 491791
0 0
Total liabilities
15 14988340
7 6951703
11 11067564
10 9803577
4 3704096
3 3213280
6 6193012
Contingencies
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Common stock
0 4624
0 4824
0 4835
0 5230
0 6360
0 6438
0 692
Additional paid-in capital
201 200847468
209 208525917
210 210495905
218 217877117
239 238780633
240 240366704
71 71034899
Accumulated other comprehensive loss
1 1250497
1 1010522
0 -217328
0 -218710
0 -229528
0 0
-8 -7574812
Accumulated deficit
-190 -189891884
-194 -193689457
-199 -198609572
-210 -210327925
-220 -220283320
-224 -223724025
-31 -31259449
Total stockholders' equity
12 12210705
16 15851806
12 11673840
7 7335712
18 18274145
17 16649117
32 32207323
Total liabilities and stockholders' equity
27 27199045
23 22803509
23 22741404
17 17139289
22 21978241
20 19862397
38 38400335
Remarks restated on Mar 8, 2012 n/a restated on Mar 14, 2013 n/a restated on Mar 11, 2014 n/a restated on Mar 11, 2015 n/a restated on Mar 11, 2016 n/a restated on Mar 14, 2017 n/a restated on Aug 14, 2017 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (51 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income (Loss)
-35
-4
-5
-12
-10
-3
194
Realization of cumulative translation adjustment
0
0
-1
0
0
0
0
Share-based compensation expense
3
3
2
1
2
1
2
Change in fair value of derivative instruments
5
-7
-1
0
-1
0
1
Impairment of assets held for sale
5
0
0
0
0
0
0
Depreciation expense
1
0
0
0
0
0
0
Debt discount and deferred financing cost accretion
5
0
0
0
0
0
0
Deferred income taxes
0
0
0
0
0
0
0
Gain on the disposal of assets held for sale
0
-1
0
0
0
0
0
Amortization of premium and discount on short-term investments
0
0
0
0
0
0
0
Restructuring expense related to property and equipment
0
0
0
0
0
0
0
Gain on the disposal of property and equipment
0
0
0
0
0
0
0
Bad debt recovery
3
0
0
0
0
0
0
Accounts receivable
1
0
2
1
1
0
0
Unbilled accounts receivable
5
1
-1
2
2
-1
0
Prepaid expenses and other current assets
-1
1
0
0
0
0
0
Other long-term assets and deferred costs
0
0
0
0
0
0
0
Accounts payable
1
-2
0
-1
-1
0
0
Accrued restructuring expenses
0
0
0
0
0
0
0
Accrued expenses and other liabilities
-9
0
0
1
-2
0
1
Accrued income taxes payable
0
0
0
0
0
0
3
Deferred revenue
0
1
1
-1
0
0
0
Net cash provided by (used in) operating activities
-15
-8
-2
-7
-8
-3
202
Purchases of available-for-sale investments
0
0
0
0
0
0
-67
Purchases of property and equipment
0
0
0
0
0
0
0
Additions to intangible assets
0
2
0
0
0
0
0
Proceeds from the sale of property and equipment
0
0
0
0
0
0
0
Net cash used in investing activities
3
2
0
0
0
0
-67
Payments of deferred offering costs
0
0
0
0
0
0
0
Proceeds from issuance of preferred stock, net of issuance costs
22
6
0
6
18
1
4
Proceeds from preferred stock subscription
0
0
0
0
0
0
0
Repayment of debt
0
0
3
-1
-1
-1
0
Net repayment of revolving credit agreement
0
0
1
0
-1
0
0
Proceeds From Repayments Of Restricted Cash Financing Activities
0
0
0
0
0
0
0
Net proceeds from exercise of warrants
3
0
0
0
1
0
0
Other
0
0
0
0
0
0
0
Net cash provided by financing activities
21
6
4
5
17
0
4
Effects of exchange rates on cash and cash equivalents
0
0
0
0
0
0
0
Net increase in cash and cash equivalents and restricted cash
9
-1
1
-2
8
-3
138
Remarks
restated on Mar 14, 2013 n/a
calculated values,
restated on Mar 11, 2014 n/a
calculated values,
restated on Mar 11, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
restated on Mar 14, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
About | Contact Forum | Legal
SimFin UG 2017 - Beta v. 1.42
Facebook | Twitter | Medium
Sumo